Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies
VANCOUVER, British Columbia, Sept. 29, 2026 — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company”), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the “Board”).
Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.
“We are pleased to welcome Melanie to Optimi’s Board,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “Her extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company board experience, will add valuable perspective as Optimi continues to execute on its strategic priorities and advance its position in the regulated psychedelic pharmaceutical market.”
Ms. Pump also currently serves on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO) and previously served as a director of BTCS Inc. Her background combines senior financial leadership with public company governance experience across a range of technology-focused and growth-oriented businesses.
“I’m pleased to join Optimi’s Board at an important stage in the Company’s development,” said Melanie Pump. “Optimi has built a strong foundation in regulated psychedelic drug manufacturing and is advancing meaningful opportunities for growth. I look forward to working with Dane, the Board and the broader leadership team, and to contributing my experience in finance, governance and emerging growth companies as Optimi continues to execute on its strategic priorities.”
The Company also announces that Leah Hodges has resigned as Corporate Secretary of the Company. Dane Stevens, the Company’s Chief Executive Officer has been appointed to fill the role. The Company thanks Mrs. Hodges for her service.
About Optimi Health Corp.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
